alexa Radioprotectors and Mitigators: Current Status | Open Access Journals
ISSN: 0975-0851
Journal of Bioequivalence & Bioavailability
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Radioprotectors and Mitigators: Current Status

Eugenia M. Yazlovitskaya1,2*

1Department of Medicine, Division of Nephrology, Vanderbilt University Medical Center, USA

2Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

*Corresponding Author:
Eugenia M. Yazlovitskaya
Department of Medicine
Division of Nephrology
Vanderbilt University Medical Center
C3210 Medical Center North 1161 21st Ave South
Nashville, TN 37232, USA
Tel: 1-615-322-6679
Fax: 1-615-343-7156
E-mail: [email protected]

Received Date: November 20, 2012; Accepted Date: November 21, 2012; Published Date: November 25, 2012

Citation: Yazlovitskaya EM (2013) Radioprotectors and Mitigators: Current Status. J Bioequiv Availab 5: e26. doi: 10.4172/jbb.10000e26

Copyright: © 2013 Yazlovitskaya EM. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Bioequivalence & Bioavailability

Editorial

Ionizing radiation (IR) is a known environmental, occupational and medical hazard that can produce dreadful health impairments. Usually, occupational exposure is low (~0.3 mSv per worker per year in the US [1]) and is only slightly higher than the exposure to the environmental radiation. However, occupational exposure could reach excessively high levels due to the accidents at nuclear power plants [2-4], exposure to contaminated waste [5], consequences of nuclear “dirty bombing” [5,6] or due to industrial accidents during mining, milling and processing of radioactive materials [7]. In these situations, the risk of exposure to high doses of radiation increases significantly not only for radiation workers but also for personnel participating in emergency response.

Medical application of IR is used mostly for the treatment of a broad range of malignancies. Multiple lines of evidence indicate that increasing the cumulative radiation dose by as little as 10-20% may facilitate the complete eradication of some tumors [8,9]. Unfortunately, elevated doses of IR cause damage to tumor-surrounding normal tissues, thus inducing detrimental side effects.

The most common therapeutic approach to safeguarding the normal tissue from deleterious effects of IR exposure is the development of radoprotectors and mitigators [10]. Radioprotectors are compounds that are designed to reduce the damage in normal tissues caused by radiation and must be present before or at the time of radiation for effectiveness. Mitigators may be used to minimize toxicity when applied even after radiation has been delivered.

Radioprotective treatments that have been proposed over the past several decades include thiol compounds that can scavenge free radicals; growth factors and cytokines that function through receptor mediated mechanisms to modify cellular response to radiation; and natural antioxidants and extracts [11-14]. Thiol compounds are the most effective and the longest studied radioprotectors. Synthetic thiol Amifostine (Ethyol) is the only FDA approved radioprotective treatment available today [15]. However, it has significant shortcomings including relatively high toxicity, unfavorable routes of administration, and narrow protection time window [14,16]. Because of its adverse side effects in humans, effectiveness of Amifostine in clinical trials is significantly diminished compared to that in animal studies [17]. Another class of radioprotectors, cytokines and immunomodulators, can only be effective if significant fraction of target cell population survives after the radiation exposure, and, thus, should be used with low radiation doses and/or in combination with radical scavengers and antioxidants [18]. These radioprotectors have common adverse side effects related to their proinflammatory activity and immunogenicity [14]. Natural antioxidants, such as vitamin E, melatonin, flavonoids and others, have fewer toxic side effects but also a lower degree of protection compared to thiol agents [14,17]. One approach to address these shortcomings has been the use of combinations of natural and synthetic compounds to increase effectiveness while lowering toxic side effects [14,17]. However, the availability of effective and safe therapeutic strategies to ameliorate radiation-induced damage is still lacking [14,17].

Encouraging pre-clinical data introduce superior and increasingly selective radioprotectors [9,19,20]. The development of some of these new agents is based on the premise that the cytotoxicity of ionizing radiation is cell-cycle dependent and include inhibitors of cyclindependent kinases (CDKs), and cell cycle regulators such as tumor suppressors pRb and p53 [20], and glycogen synthase kinase 3β (GSK- 3β) [21,22]. Most important, these inhibitors are highly selective and protect only normal cells [21-23]. The other group of novel radioprotectors includes free radical scavenges with the safer profiles compared to Amifostine. For example, pyridoxamine (PM) was shown to be more effective at protecting from radiation-induced damage to normal tissue than Amifostine [24]; at the same time PM is well tolerated, with no significant treatment-related adverse effects [25].

Radiation mitigators aim to interrupt IR-induced damage or intervene to prevent the perpetuation of damage and thus reduce the overall toxicity. Alternatively, radiation mitigators can be the agents delivered during or shortly after exposure to repopulate a critical cell compartment such as the mucosa or bone marrow. In this instance, the mitigator is used to prevent acute toxicity. Many cytokines and growth factors have radiation mitigating effects: granulocyte-colony stimulating factor (G-CSF) [26], keratinocyte growth factor (KGF) [27], agonists for toll-like receptors 5 [28] and 2/6 [29].

These emerging radioprotectors and mitigators present novel strategies for reduction of deleterious consequences of normal tissue irradiation, as well as for radiosensitization of tumors.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11759
  • [From(publication date):
    January-2013 - Aug 23, 2017]
  • Breakdown by view type
  • HTML page views : 7933
  • PDF downloads :3826
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]e.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords